9999999997-17-000378.txt : 20170127
9999999997-17-000378.hdr.sgml : 20170127
20170127083401
ACCESSION NUMBER: 9999999997-17-000378
CONFORMED SUBMISSION TYPE: CT ORDER
PUBLIC DOCUMENT COUNT: 1
FILED AS OF DATE: 20170127
DATE AS OF CHANGE: 20170127
20170126
20170127
FILER:
COMPANY DATA:
COMPANY CONFORMED NAME: Jounce Therapeutics, Inc.
CENTRAL INDEX KEY: 0001640455
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
IRS NUMBER: 000000000
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
FILING VALUES:
FORM TYPE: CT ORDER
SEC ACT: 1933 Act
SEC FILE NUMBER: 333-215372
FILM NUMBER: 17551650
BUSINESS ADDRESS:
STREET 1: 1030 MASSACHUSETTS AVE.
CITY: CAMBRIDGE
STATE: MA
ZIP: 02138
BUSINESS PHONE: 857-259-3840
MAIL ADDRESS:
STREET 1: 1030 MASSACHUSETTS AVE.
CITY: CAMBRIDGE
STATE: MA
ZIP: 02138
CT ORDER
1
filename1.pdf
begin 644 filename1.pdf
M)5!$1BTQ+C4-)>+CS],-"C$P(# @;V)J#3P\+TQI;F5A7!E+UA2968O5ULQ(#(@,5T^/G-T#9 &$S\@"$& G5,$=@T*96YD%LP(# @-C$R(#I'KP@VPH@:1M
MNL&2A=JT@Y 7FJ,F!C\$6V7IMY].LA,WK!MK$+*D^]_I[JP?"X$"$R!B8!$P
MSRPQ>((#I\9&@3-@U.C7U^3NH.\3+;4R^_N$812%A_&8S.I*&UN:<@PV-K/U
M,=+)RZ;.$J579'D[(ZDZZ/5X;-R_+^%9%JTRFSDPDDRZ8S('>D4Y25_WZI23
MU'NGV]A)FZE*0Q0S.4AVNKSF29%Z^?TKQ4+2S4+WBH2UE]MMI"EHI8Q0C6ODQ&T[K8
MS%.K)[I1.MN11=V4LK"F)U>2,!5]U;+(LTFU+110DFA5/IK_'+K^T!=+;O*]
MKAOR8]"*;70J6X4^[Z6_J[)ZDU=;\I17DZK-C^=9WK3Z9B<;\/A9%GQH?*1O
MLO-@W/S^EY\:"TJ;%V4K.Y9GKM[H7;OB 04< 77K<*#F>1XX'_3XV_S3'8+S
M[HLS# 6$C($0D9U>%'\78:R _F':Z6I:Z>(7M(]'F]
M?78^T"SQM*?PMP # :$B&\-"F5N9'-T
MA%;;;N,V$'WW5PS0%ZFPN**N]KXYOF0=- Y@*T"!I"ADB;99*)*7HC:;O^_P
M(L=VLJV#2+P>GIDY,]27VPV%?3NXR09?LBP "MEN0 /P\0]?H9] ZH_(*(+L
M9>##'O^S0CU>!PZXV3_8]"BA,60S.Y#];AM>2,;C]UF/^#X=J]VV\3IXA$9.S/8N%Y,4B=S"74FF1F=VT%P_\KN!EY"TC2^Q$2&!E,U%.9F/GU<
M+[.EBZLC!(#):@9X2$@2Y\_IM\GJUG9@^G!_O]QLE@\K Y\22J_ :0].M=WEX@V"9 B!3U-M*&+%9Z2N/>31@/C1%6[O"-\ZXF$]FZ_AUO5&:/QZLLJ6
MJUODMUIH8H@011B1?G=@=\>!V;V;2DZ=TU7%PRR Q/YD762
M%^T0EFY$8J=V*3X+8OC%Y+_\AL$^TX^SX!6#54,@#$,OH'&8!N#!=/%;& 9I
M9+B1^,QBP5O)Z;YR#B:0R)>K/#B)S
M=M'4._1EY/"2U9+GN#%P*I""F:9\<RG
MT1IFP3@V8CNEETY>:WM1=25:M!.-,C!R0!X8S'\>^);+%F0#.2P:8>+6S?X"+>FEG@DS#^S%U]
M.=*JT&YO70_];?4A#[D>E"[22Y03>:L#I$+5N"I>QH7&*<:']K +;9[T$6E]
M.-^[O.([SEK(6U!:L3*IL//RPD2AFHV '=<9@S4RB<]*BQ59G==Z(3)JA*JD
MB:/H]'(Q^E6!7PC&RL;,0;/K@VU@3T2Q1"D@DQ$&8E+((<3P2#9D2B".@V=G
M^^P^.]&S.]3(,_Z#&T4B]H?@/SFM0L$3IXTX-E8["ZZ(,SB@[263#$],R2]EO=2"7>8[?%+*W>H.1M434MP]0@8*J+3T;)>Z3I*=+4$)H4
M12-*S-_J;8C99/.$&\-3O,SROIC']$PQHQ/.R.!H2VQZ)2:]=DU5-:^J-#"3
M:+T@0A)>7XB]GE]Y58&R:HME8>0P5!\FI& 5RUL7A[-
MOL0OK$>FF#TZBKQ5RANJ[*^N5$.#AR!KTCI1;TP
MS+7QNU1]E4PV#G>JKRX08OIV>*%>%(=YOUX!Q2$V*HV/C=(L;7N$\_O.%% M
MFN@D&OQM6"&8Q&\OE!XFA8O?@7!E+T]B:E-T;3X^R (L'Z+G9V $& (V%"#<-"F5N9'-T7!E+UA-3"]4>7!E
M+TUE=&%D871A/CYS=')E86T-"CP_>'!A8VME="!B96=I;CTB[[N_(B!I9#TB
M5S5-,$UP0V5H:4AZDY48WIK8SED(C\^"CQX.GAM<&UE=&$@>&UL;G,Z
M>#TB861O8F4Z;G,Z;65T82\B('@Z>&UP=&L](D%D;V)E(%A-4"!#;W)E(#4N
M-"UC,# V(#@P+C$U.3@R-2P@,C Q-B\P.2\Q-BTP,SHS,3HP." @(" @(" @
M(CX*(" @/')D9CI21$8@>&UL;G,Z6YT87@M;G,C(CX*(" @(" @/')D9CI$97-C&UL;G,Z>&UP/2)H='1P
M.B\O;G,N861O8F4N8V]M+WAA<"\Q+C O(@H@(" @(" @(" @("!X;6QN&UL;G,Z>&UP34T](FAT=' Z+R]N&%P+S$N,"]M;2\B/@H@(" @(" @(" \>&UP.D-R96%T;W)4;V]L/E!38W)I
M<'0U+F1L;"!697)S:6]N(#4N,BXR/"]X;7 Z0W)E871O&UP34TZ26YS=&%N8V5)1#YU=6ED.F(R9#1B9&,W
M+3DR,F8M-&0T-BUA-V0W+68U96$U-&4W-V$W9#PO>&UP34TZ26YS=&%N8V5)
M1#X*(" @(" @/"]R9&8Z1&5S8W)I<'1I;VX^"B @(#POJ'5!:DZ@?(RQ#H(P% !_Y6VT Z4M$M00$B(K"8E&%A:D
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M+TE$6SPQ03E$-#9"03)$,D%#.3 X,SYX%&PT*96YD